[go: up one dir, main page]

MX2013004879A - Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica. - Google Patents

Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.

Info

Publication number
MX2013004879A
MX2013004879A MX2013004879A MX2013004879A MX2013004879A MX 2013004879 A MX2013004879 A MX 2013004879A MX 2013004879 A MX2013004879 A MX 2013004879A MX 2013004879 A MX2013004879 A MX 2013004879A MX 2013004879 A MX2013004879 A MX 2013004879A
Authority
MX
Mexico
Prior art keywords
macular degeneration
related macular
advanced age
polygenic score
predicting progression
Prior art date
Application number
MX2013004879A
Other languages
English (en)
Other versions
MX348025B (es
Inventor
Timothy W Behrens
Robert R Graham
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013004879A publication Critical patent/MX2013004879A/es
Publication of MX348025B publication Critical patent/MX348025B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

La presente invención se relaciona con métodos para la identificación de individuos con degeneración macular intermedia relacionada con la edad (AMD) quienes' tienen un mayor riesgo de pasar a la AMD avanzada, utilizando una puntuación poligénica calculada sobre la base de los resultados de los estudios de asociación génica en todo el genoma, que utiliza miles de polimorfismos de un solo nucleótido (SNP).
MX2013004879A 2010-11-01 2011-11-01 Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica. MX348025B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40903910P 2010-11-01 2010-11-01
US201161573602P 2011-09-09 2011-09-09
PCT/US2011/058829 WO2012061421A1 (en) 2010-11-01 2011-11-01 Predicting progression to advanced age-related macular degeneration using a polygenic score

Publications (2)

Publication Number Publication Date
MX2013004879A true MX2013004879A (es) 2013-07-02
MX348025B MX348025B (es) 2017-05-24

Family

ID=45002128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004879A MX348025B (es) 2010-11-01 2011-11-01 Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.

Country Status (22)

Country Link
US (3) US20120107315A1 (es)
EP (2) EP3170905A1 (es)
JP (4) JP2013544512A (es)
KR (1) KR20130130732A (es)
CN (1) CN103201393B (es)
AR (1) AR083677A1 (es)
AU (2) AU2011323487B2 (es)
BR (1) BR112013010769A2 (es)
CA (1) CA2816805A1 (es)
DK (1) DK2635704T3 (es)
ES (1) ES2628806T3 (es)
HU (1) HUE032938T2 (es)
IL (1) IL226063A0 (es)
MX (1) MX348025B (es)
NZ (1) NZ610067A (es)
PL (1) PL2635704T3 (es)
RU (2) RU2016127684A (es)
SG (2) SG10201605904PA (es)
SI (1) SI2635704T1 (es)
TW (1) TW201250003A (es)
WO (1) WO2012061421A1 (es)
ZA (1) ZA201303001B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893478A1 (en) * 2012-09-06 2015-07-15 Ancestry.com DNA, LLC Using haplotypes to infer ancestral origins for recently admixed individuals
US9737205B2 (en) 2013-07-31 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Method and system for evaluating progression of age-related macular degeneration
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
RU2559090C1 (ru) * 2014-08-27 2015-08-10 Александр Владимирович Кулик Способ прогнозирования персонифицированного риска развития макулодистрофии
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2019506159A (ja) 2016-01-20 2019-03-07 ヴィトリサ セラピューティクス， インコーポレイテッド Ｄ因子を阻害するための組成物および方法
CN106086222A (zh) * 2016-08-24 2016-11-09 厦门美因生物科技有限公司 基于qPCR分型技术的运动基因检测评估方法及系统
IL266173B2 (en) * 2016-10-30 2024-09-01 Taliaz Ltd Method and system for predicting response of a subject to antidepressant treatment
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3622660B1 (en) * 2017-05-12 2023-08-30 Massachusetts Institute of Technology Systems and methods for crowdsourcing, analyzing, and/or matching personal data
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN109585017B (zh) * 2019-01-31 2023-12-12 上海宝藤生物医药科技股份有限公司 一种年龄相关性黄斑变性的风险预测算法模型和装置
US12100480B2 (en) 2019-08-27 2024-09-24 The Board Of Trustees Of The Leland Stanford Junior University Assessment of polygenic trait risk via trait components and applications thereof
KR20220006010A (ko) * 2020-07-07 2022-01-14 주식회사 카나프테라퓨틱스 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도
RU2758662C1 (ru) * 2021-03-19 2021-11-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ определения показаний к антиангиогенной терапии при подозрении на влажную форму возрастной макулярной дегенерации
WO2024186766A1 (en) * 2023-03-03 2024-09-12 The City University Of New York Use of extracellular vesicles as biomarkers for age-related macular degeneration

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US6379929B1 (en) * 1996-11-20 2002-04-30 The Regents Of The University Of Michigan Chip-based isothermal amplification devices and methods
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
CA2439735A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
RU2186392C1 (ru) * 2001-04-26 2002-07-27 Должич Галина Ивановна Способ диагностики сенильной макулярной дистрофии сетчатки
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
CN1950826A (zh) * 2004-03-05 2007-04-18 佩勒根科学有限公司 遗传分析的方法
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US7527970B2 (en) 2004-10-15 2009-05-05 The United States Of America As Represented By The Department Of Health And Human Services Method of identifying active chromatin domains
JP5068175B2 (ja) * 2005-01-04 2012-11-07 日立化成工業株式会社 プライマー生成ローリングサークル型増幅
EP2377951A1 (en) * 2005-02-14 2011-10-19 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2006133295A2 (en) * 2005-06-08 2006-12-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY (ARM) ON CHROMOSOME 10q26
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
JP2010526555A (ja) * 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2009029587A2 (en) * 2007-08-24 2009-03-05 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
EP2283163B1 (en) * 2008-04-18 2015-07-08 Tufts Medical Center Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
AT506998B1 (de) * 2008-06-30 2010-03-15 Fronius Int Gmbh Kontaktrohr für einen schweissbrenner
US20120115925A1 (en) * 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
WO2010085542A2 (en) * 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)

Also Published As

Publication number Publication date
EP3170905A1 (en) 2017-05-24
RU2016127684A3 (es) 2018-12-06
KR20130130732A (ko) 2013-12-02
WO2012061421A1 (en) 2012-05-10
CN103201393A (zh) 2013-07-10
MX348025B (es) 2017-05-24
JP2018068285A (ja) 2018-05-10
SI2635704T1 (sl) 2017-07-31
AR083677A1 (es) 2013-03-13
DK2635704T3 (en) 2017-06-19
BR112013010769A2 (pt) 2019-09-24
US20120107315A1 (en) 2012-05-03
JP2013544512A (ja) 2013-12-19
CA2816805A1 (en) 2012-05-10
PL2635704T3 (pl) 2017-09-29
EP2635704B1 (en) 2017-04-19
NZ610067A (en) 2015-05-29
SG10201605904PA (en) 2016-09-29
RU2593954C2 (ru) 2016-08-10
CN103201393B (zh) 2019-01-18
US20180163262A1 (en) 2018-06-14
AU2011323487B2 (en) 2016-08-11
EP2635704A1 (en) 2013-09-11
TW201250003A (en) 2012-12-16
AU2011323487A1 (en) 2013-06-13
HUE032938T2 (hu) 2017-11-28
AU2016256692A1 (en) 2016-11-24
IL226063A0 (en) 2013-06-27
JP2019216732A (ja) 2019-12-26
JP2016154538A (ja) 2016-09-01
ZA201303001B (en) 2014-10-29
ES2628806T3 (es) 2017-08-04
US20140286947A1 (en) 2014-09-25
SG190078A1 (en) 2013-06-28
RU2013125230A (ru) 2014-12-10
RU2016127684A (ru) 2018-12-06

Similar Documents

Publication Publication Date Title
MX348025B (es) Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
MX2007009565A (es) Metodos y reactivos para tratamiento y diagnostico de degeneracion macular relacionada con la edad.
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
EP2342335A4 (en) NEW GROUP OF GENES
EP2639328A4 (en) High-strength spring steel, method for producing high-strength spring, and high-strength spring
WO2011044458A8 (en) Compositions and methods for diagnosing genome related diseases and disorders
WO2012166626A8 (en) Reagents and methods for treating dental disease
SI2417267T1 (sl) Postopek zdravljenja na podlagi polimorfizmov gena KCNQ1
WO2013177248A3 (en) Modulation of enhancer rna mediated gene expression
MX349801B (es) Sustratos de enzimas de ácido nucleico.
TN2013000385A1 (en) Processes for the manufacture of macrocyclic depsipeptides and new intermediates
PH12015501176B1 (en) Primers, snp markers and method for genotyping mycobacterium tuberculosis
MY158910A (en) Surface modified silicic acid semi-gels
WO2010127290A3 (en) Improved isoprene hydrocarbon production using genetically engineered cyanobacteria
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
MY156873A (en) Novel forms of a multicyclic compound
EP2679698A4 (en) Cold-work tool steel exhibiting superior machinability
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
EP2562267A3 (en) Method and kit for identifying Phalaenopsis varieties
WO2012038837A3 (en) Methods for predicting response to anti-cancer therapy in cancer patients
MX2009005810A (es) Celulas hospederas optimizadas para la produccion de proteinas.
WO2010081764A3 (de) Genomweite analyse zur endothelialen dysfunktion
WO2012073495A3 (en) Sugarcane-stalk-number-related marker and the use thereof

Legal Events

Date Code Title Description
FG Grant or registration